Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

BACKGROUND: Nanoliposomal irinotecan plus fluorouracil/leucovorin (5-FU/LV) is a standard second-line therapy for patients with pancreatic cancer. Identification of biomarkers is important to determine appropriate treatment strategies. We investigated the clinical practice outcomes and biomarkers as...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Takeshi, Todaka, Akiko, Oshima, Kotoe, Fushiki, Kunihiro, Hamauchi, Satoshi, Tsushima, Takahiro, Yokota, Tomoya, Onozawa, Yusuke, Yasui, Hirofumi, Yamazaki, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854093/
https://www.ncbi.nlm.nih.gov/pubmed/36670426
http://dx.doi.org/10.1186/s12885-023-10542-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854093/
https://www.ncbi.nlm.nih.gov/pubmed/36670426
http://dx.doi.org/10.1186/s12885-023-10542-w

Ejemplares similares